Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10636 (
tau protein
)
5,110
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MARK/Par-1 is a kinase involved in development of embryonic polarity. In neurons, MARK phosphorylates
tau protein
and causes its detachment from microtubules, the tracks of axonal transport. Because the target sites of MARK on tau occur at an early stage of Alzheimer neurodegeneration, we searched for interaction partners of MARK. Here we report that MARK2 is negatively regulated by
PAK5
, a neuronal member of the p21-activated kinase family.
PAK5
suppresses the activity of MARK2 toward its target,
tau protein
. The inhibition requires the binding between the
PAK5
and MARK2 catalytic domains, but does not require phosphorylation. In transfected Chinese hamster ovary (CHO) cells both kinases show a vesicular distribution with partial colocalization on endosomes containing AP-1/2. Although MARK2 transfected alone destabilizes microtubules and stabilizes actin stress fibers,
PAK5
keeps microtubules stable through the down-regulation of MARK2 but destabilizes the F-actin network so that stress fibers and focal adhesions disappear and cells develop filopodia. The results point to an inverse relationship between actin- and microtubule-related signaling by the
PAK5
and MARK2 pathways that affect both cytoskeletal networks.
...
PMID:PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. 1601 8